Suggested remit: To appraise the clinical and cost effectiveness of adagrasib within its marketing authorisation for treating KRAS G12C mutation positive advanced NSCLC which has been previously treated, or is not suitable for treatment, with platinum based chemotherapy and/or anti-PD-1/PD-L1 immunotherapy.
 
Status In progress
Technology type Medicine
Decision Awaiting decision
Process STA Standard
ID number 6339

Provisional Schedule

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6339 09 July 2024 - 06 August 2024

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
09 July 2024 In progress. Scoping commenced.
19 October 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected
26 June 2023 Topic selection

For further information on our processes and methods, please see our CHTE processes and methods manual